NCT02104700View on ClinicalTrials.gov

Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

July 31, 2016

Conditions

HIV

Interventions

DRUG

Rilpivirine/Emtricitabine/Tenofovir

Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday

Trial Locations (1)

Unknown

Rwanda Military Hospital, Kinombe

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Philip Grant

OTHER